New Therapy Studied for OCD Patients
Posted on: Thursday, 23 February 2006, 15:00 CST
University of Rochester scientists are studying whether a new therapy for Parkinson's disease might also help treat obsessive-compulsive disorder.
The study, part of a five-year, $3.5 million federal grant, involves measuring whether a therapy called Deep Brain Stimulation can reduce the rampant anxiety that keeps some OCD patients homebound.
DBS uses implanted microstimulators to block abnormal nerve signals sent between brain structures. Researchers have successfully used such so-called brain pacemakers to treat movement disorders, such as those produced by Parkinson's disease.
The researchers will also attempt to determine exactly which brain network is disrupted in OCD in hopes of fine-tuning treatment.
OCD, a chronic anxiety disorder affecting 2.2 million Americans, inflicts patients with obsessions and the urgent need to repeat behaviors that can relieve anxiety.
DBS is one of the most promising areas of OCD research because early studies show it may help many within the approximately 20 percent of OCD patients for whom neither psychological nor drug therapy works, said Suzanne Haber, a professor of pharmacology and physiology and lead investigator for the grant.
Source: United Press International
Related Articles
- Avastin approved for brain cancer therapy
- Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients With Multiple Sclerosis
- More Than Two-Thirds of Newly-Diagnosed Patients Who Are Prescribed Medications for OCD Receive Inadequate Therapy
- A Different Target for Brain Tumor Therapy
- Non-Surgical Brain-Cancer Therapy Proposed
- Study Using New Imaging Technology Detects Subtle Brain Changes in Patients With Type 1 Diabetes
- Targepeutics, Inc. Announces New Approaches to Brain Tumor Therapy Consortium (NABTT) Relationship
- Peregrine Pharmaceuticals and New Approaches to Brain Tumor Therapy (NABTT) Consortium Initiate Cotara(R) Brain Cancer Trial
- Peregrine and New Approaches to Brain Tumor Therapy (NABTT) Consortium Receive Approval for Cotara(R) Brain Cancer Protocol
- Peregrine Pharmaceuticals and New Approaches to Brain Tumor Therapy (NABTT) Consortium Enter Collaboration to Treat Brain Cancer Patients
 |
 |
User Comments (1)
| 1. |
Posted by Jessica on 02/18/2009, 18:53 no answers grrrr |
RSS Feeds